Biology subjects

Simicic, D.

Publications and source records attributed to Simicic, D..

11 recordsLinked to original sources

bioRxiv2026

Metabolite Relaxation Times at 3T From Birth to 7 Years

PurposeWith growing interest in pediatric MRS to understand the neurochemistry of brain development, it is essential to establish pediatric-specific metabolite T1 and T2 relaxation times for reliable quantification of metabolites. Furthermore, characterization of age-related changes in relaxation times may provide insight into developmental differences in tissue microstructure and cellular composition. Therefore, the goals of this study were two-fold: (1) to estimate metabolite T1 and T2 relaxation times in a pediatric cohort; and (2) to assess linear relationships between age and relaxation times. MethodsTI- and TE-series data were acquired from the bilateral thalamus in 20 and 25 participants aged between 0 and 7 years, respectively. Data were processed and modelled in Osprey 2.5.0. Metabolite T1 and T2 relaxation times of total N-acetylaspartate at 2.0 ppm (tNAA2.0), total creatine at 3.0 ppm (tCr3.0), total creatine at 3.9 ppm (tCr3.9), total choline (tCho), myo-inositol (mI) and the combined glutamate and glutamine (Glx) were estimated by fitting the modelled signal amplitudes to TI-series inversion recovery signal and TE-series exponential decay equations, respectively. Linear relationships with age were tested for metabolite T1 and T2 relaxation times using Spearman correlations. ResultstNAA2.0 and Glx showed significant changes in T1 with age. tNAA2.0, tCr3.0, tCho and mI showed significant decrease in T2 with age. ConclusionSeveral metabolites showed significant changes in relaxation times with age in the thalamus region. Therefore, use of age-specific relaxation correction for pediatric studies using the linear equations provided is encouraged for reliable quantification of metabolites.

neuroscience↗

bioRxiv2026

Real-time AI integration for MR to detect artifacts and guide pulse sequence adaptations

This work presents a first-of-its-kind artificial intelligence (AI-)integrated MR pulse sequence that detects out-of-voxel (OOV) artifacts in real-time (within-TR) and responds prospectively by updating the crusher gradient scheme. Per Excitation Real-time Execution & Guided Responses with Integrated Neural-network Evaluation (PEREGRINE), allows for deployment of deep learning models and pulse sequence updates. In this study, PEREGRINE operated a time-domain (TD) and frequency-domain (FD) convolutional autoencoder that detect OOV artifacts. Scans without (AI-off) and with (AI-on) updates were collected from the medial prefrontal cortex of healthy volunteers using a MEGA-edited MRS experiment. The degree of OOV contamination (OOV Score) was quantified per transient based upon the prevalence of OOV signals in the TD and FD data. OOV Scores above a user-defined threshold triggered an update of the crusher gradient scheme, iterating through 48 permutations (6 axis transpositions x 8 polarity flips). Within each 2-second TR, PEREGRINE successfully provided single-transient OOV Scores and updated gradients accordingly. No difference was observed between the OOV Scores from the full ("Full" condition) AI-on and AI-off sessions due to the AI-on scan cycling over better and worse gradient permutations relative to the AI-off scan. However, the AI-on scan had significantly lower OOV Scores than the AI-off scan when selecting the transients where PEREGRINE persisted ("Dwell" condition) on a given gradient permutation. Ultimately, Fit Quality Number (FQN) from linear combination modeling improved significantly for the AI-on compared to the AI-off scan. PEREGRINE enabled an adaptive and AI-integrated sequence allowing for real-time evaluation and response to OOV artifacts, identifying gradient modifications that produced less OOV contamination. Graphical AbstractO_ST_ABSGraphical Abstract SummaryC_ST_ABSPEREGRINE, Per Excitation Real-time Execution & Guided Responses with Integrated Neural-network Evaluation, allows for pulse sequence updates using on-scanner deployed neural networks. To demonstrate the utility, PEREGRINE was used to operate two neural networks (time/frequency domain), trained to detect out-of-voxel artifacts, during a MEGA-edited MRS experiment in the prefrontal cortex. When artifacts were detected, PEREGRINE updated the crusher gradients within the same TR. Real-time, adaptive, and AI-driven MR will provide a long-awaited solution for combatting artifacts and poor data quality. O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=167 SRC="FIGDIR/small/722724v2_ufig1.gif" ALT="Figure 1"> View larger version (38K): org.highwire.dtl.DTLVardef@cc01e0org.highwire.dtl.DTLVardef@18f4083org.highwire.dtl.DTLVardef@1d48c8corg.highwire.dtl.DTLVardef@1574ba7_HPS_FORMAT_FIGEXP M_FIG Graphical Abstract Figure C_FIG

neuroscience↗

bioRxiv2025

Gradient scheme optimization for PRESS-localized edited MRS using weighted pathway suppression

This study aimed to design and implement an optimized gradient scheme for PRESS-localized edited magnetic resonance spectroscopy (MRS) to enhance suppression of out-of-voxel (OOV) artifacts. These artifacts, which originate from insufficient crushing of unwanted coherence transfer pathways (CTPs), are particularly challenging in editing schemes for metabolites like gamma-aminobutyric acid and glutathione. To address this, a volume-based likelihood model was developed to guide gradient scheme optimization, prioritizing suppression of CTPs based on likelihood. A volume-based likelihood model for CTP weighting was integrated into a Dephasing optimization through coherence order pathway selection (DOTCOPS) gradient optimization. Using a genetic algorithm with a new dual-penalty cost function, gradient schemes were optimized to maximize pathway-specific suppression. Hardware and sequence constraints, maximum gradient amplitudes and delay durations respectively, informed the optimization. Validation of the optimized scheme was performed with simulations by calculating the k-space crushing efficiency analytically with k-space trajectory. and in vivo using an edited MRS sequence in three brain regions (posterior cingulate cortex PCC, thalamus, and medial prefrontal cortex (mPFC)), with particular focus on OOV artifact reduction and spectral quality improvements. A three-way Analysis of Variance was used to assess the significance level of OOV artifact reduction. The optimized gradient scheme demonstrated improved k-space crushing efficiency (by an average of 197%). OOV artifacts were reduced in all brain regions, particularly in highly OOV-susceptible regions (thalamus and mPFC). Improvements were most notable around 4.3 ppm with significant OOV artifact amplitude reductions (p < 0.001). By using a volume-based likelihood model for CTP prioritization, the optimized DOTCOPS scheme ensures robust and region-agnostic performance in reducing OOV artifacts.

neuroscience↗

bioRxiv2025

Identifying out-of-voxel echoes in edited MRS with phase cycle inversion

1.PurposeTo identify the origin of out-of-voxel (OOV) signals based on the coherence transfer pathway (CTP) formalism using signal phase conferred by the acquisition phase cycling scheme. Knowing the CTP driving OOV artifacts enables optimization of crusher gradients to improve their suppression without additional data acquisition. Theory and MethodsA phase cycle systematically changes the phase of RF pulses across the transients of an experiment, encoding phase shifts into the data that can be used to suppress unwanted CTPs. We present a new approach, phase cycle inversion (PCI), which removes the receiver phase originally applied to the stored transients, replacing it with new receiver phases, matching the phase evolutions associated with each unwanted CTP, to identify the OOV signals. We demonstrated the efficacy of PCI using the MEGA-edited PRESS sequence in simulations, phantom and in vivo experiments. Based on these findings, the crusher gradient scheme was optimized. ResultsThe simulation results demonstrated that PCI can fully separate signals originating from different CTPs using a complete phase cycling scheme. PCI effectively identified the CTP responsible for OOV signals in phantom experiments and in vivo, though with reduced specificity in vivo due to phase instabilities. Re-optimization of the gradient scheme based on the identified OOV-associated CTP to suppress these signals, resulted in cleaner spectra in six volunteers. ConclusionPCI can be broadly applied across pulse sequences and voxel locations, making it a flexible and generalizable approach for diagnosing the CTP origin of OOV signals.

neuroscience↗

bioRxiv2024

Age dependency of neurometabolite T1 relaxation times

PurposeTo measure T1 relaxation times of metabolites at 3T in a healthy aging population and investigate age dependence. MethodsA cohort of 101 healthy adults were recruited with approximately 10 male and 10 female participants in each decade band: 18-29, 30-39, 40-49, 50-59, and 60+ years old. Inversion-recovery PRESS data (TE/TR: 30/2000 ms) were acquired at 8 inversion times (TIs) (300, 400, 511, 637, 780, 947, 1148 and 1400 ms) from voxels in white-matter-rich centrum semiovale (CSO) and gray-matter-rich posterior cingulate cortex (PCC). Modeling of TI-series spectra was performed in Osprey 2.5.0. Quantified metabolite amplitudes for total N-acetylaspartate (tNAA2.0), total creatine at 3.0 ppm (tCr3.0) and 3.9 ppm (tCr3.9), total choline (tCho), myo-inositol (mI), and the sum of glutamine and glutamate (Glx) were modeled to calculate T1 relaxation times of metabolites. ResultsT1 relaxation times of tNAA2.0 in CSO and tNAA2.0, tCr3.0, mI and Glx in PCC decreased with age. These correlations remained significant when controlling for cortical atrophy. T1 relaxation times were significantly different between PCC and CSO for all metabolites except tCr3.0. We also propose linear models for predicting metabolite T1s at 3T to be used in future aging studies. ConclusionMetabolite T1 relaxation times change significantly with age, an effect that will be important to consider for accurate quantitative MRS, particularly in studies of aging.

neuroscience↗

bioRxiv2024

A Water Relaxation Atlas for Age and Region specific Metabolite Concentration Correction

Metabolite concentration estimates from Magnetic Resonance Spectroscopy (MRS) are typically quantified using water referencing, correcting for relaxation-time differences between metabolites and water. One common approach is to correct the water reference signal for differential relaxation within three tissue compartments (gray matter, white matter, and cerebrospinal fluid) using fixed literature values. However, water relaxation times (T1 and T2) vary between brain locations, in pathology, and with age. MRS studies, even those measuring metabolite levels across the lifespan, often ignore these effects, because of a lack of reference data. The purpose of this study is to develop a water relaxometry atlas and to integrate location- and age-appropriate relaxation values into the MRS analysis workflow. 101 volunteers (51 men, 50 women; [~]10 male and 10 female participants per decade (from the 20s to 60s), were recruited. T1-weighted MPRAGE images ((1-mm)3 isotropic resolution) were acquired. Whole-brain water T1 and T2 measurements were made with DESPOT ((1.4 mm)3 isotropic resolution). T1 and T2 maps were registered to the JHU MNI-SS/EVE atlas using affine and LDDMM transformation. The atlass 268 parcels were reduced to 130 by combining homologous parcels. Mean T1 and T2 values were calculated for each parcel in each subject. Linear models of T1 and T2 as functions of age were computed, using age - 30 as the predictor. Reference atlases of "age-30-intercept" and age-slope for T1 and T2 were generated. The atlas-based workflow was integrated into Osprey, which co-registers MRS voxels to the atlas and calculates location- and age-appropriate water relaxation parameters for quantification. The water relaxation aging atlas revealed significant regional and tissue differences in water relaxation behavior across adulthood. Using location- and subject-appropriate reference values in the MRS analysis workflow removes a current methodological limitation and is expected to reduce quantification biases associated with water-referenced tissue correction, especially for studies of aging.

neuroscience↗

bioRxiv2024

Data-driven determination of 1H-MRS basis set composition

PurposeMetabolite amplitude estimates derived from linear combination modeling of MR spectra depend upon the precise list of constituent metabolite basis functions used (the "basis set"). The absence of clear consensus on the "ideal" composition or objective criteria to determine the suitability of a particular basis set contributes to the poor reproducibility of MRS. In this proof-of-concept study, we demonstrate a novel, data-driven approach for deciding the basis-set composition using Akaike information criteria (AIC). MethodsWe have developed an algorithm that iteratively adds metabolites to the basis set using iterative modeling, informed by AIC scores. We investigated two quantitative "stopping conditions", referred to as max-AIC and zero-amplitude, and whether to optimize the selection of basis set on a per-spectrum basis or at the group level. The algorithm was tested using two groups of synthetic in-vivo-like spectra representing healthy brain and tumor spectra, respectively, and the derived basis sets (and metabolite amplitude estimates) were compared to the ground truth. ResultsAll derived basis sets correctly identified high-concentration metabolites and provided reasonable fits of the spectra. At the single-spectrum level, the two stopping conditions derived the underlying basis set with 84-88% accuracy. When optimizing across a group, basis set determination accuracy improved to 89-92%. ConclusionData-driven determination of the basis set composition is feasible. With refinement, this approach could provide a valuable data-driven way to derive or refine basis sets, reducing the operator bias of MRS analyses, enhancing the objectivity of quantitative analyses, and increasing the clinical viability of MRS.

neuroscience↗

bioRxiv2024

Comparison of test-retest reproducibility of DESPOT and 3D-QALAS for water T1 and T2 mapping

PurposeRelaxometry, specifically T1 and T2 mapping, has become an essential technique for assessing the properties of biological tissues related to various physiological and pathological conditions. Many techniques are being used to estimate T1 and T2 relaxation times, ranging from the traditional inversion or saturation recovery and spin-echo sequences to more advanced methods. Choosing the appropriate method for a specific application is critical since the precision and accuracy of T1 and T2 measurements are influenced by a variety of factors including the pulse sequence and its parameters, the inherent properties of the tissue being examined, the MRI hardware, and the image reconstruction. The aim of this study is to evaluate and compare the test-retest reproducibility of two advanced MRI relaxometry techniques (Driven Equilibrium Single Pulse Observation of T1 and T2, DESPOT, and 3D Quantification using an interleaved Look-Locker acquisition Sequence with a T2 preparation pulse, QALAS), for T1 and T2 mapping in a healthy volunteer cohort. Methods10 healthy volunteers underwent brain MRI at 1.3 mm3 isotropic resolution, acquiring DESPOT and QALAS data ([~]11.8 and [~]5 minutes duration, including field maps, respectively), test-retest with subject repositioning, on a 3.0 Tesla Philips Ingenia Elition scanner. To reconstruct the T1 and T2 maps, we used an equation-based algorithm for DESPOT and a dictionary-based algorithm that incorporates inversion efficiency and B1-field inhomogeneity for QALAS. The test-retest reproducibility was assessed using the coefficient of variation (CoV), intraclass correlation coefficient (ICC) and Bland-Altman plots. ResultsOur results indicate that both the DESPOT and QALAS techniques demonstrate good levels of test-retest reproducibility for T1 and T2 mapping across the brain. Higher whole-brain voxel-to-voxel ICCs are observed in QALAS for T1 (0.84 {+/-} 0.039) and in DESPOT for T2 (0.897 {+/-} 0.029). The Bland-Altman plots show smaller bias and variability of T1 estimates for QALAS (mean of -0.02 s, and upper and lower limits of -0.14 and 0.11 s, 95% CI) than for DESPOT (mean of -0.02 s, and limits of -0.31 and 0.27 s). QALAS also showed less variability (mean 1.08 ms, limits -1.88 to 4.04 ms) for T2 compared to DESPOT (mean of 2.56 ms, and limits -17.29 to 22.41 ms). The within-subject CoVs for QALAS range from 0.6% (T2 in CSF) to 5.8% (T2 in GM), while for DESPOT they range from 2.1% (T2 in CSF) to 6.7% (T2 in GM). The between-subject CoVs for QALAS range from 2.5% (T2 in GM) to 12% (T2 in CSF), and for DESPOT they range from 3.7% (T2 in WM) to 9.3% (T2 in CSF). ConclusionOverall, QALAS demonstrated better reproducibility for T1 and T2 measurements than DESPOT, in addition to reduced acquisition time.

neuroscience↗

bioRxiv2024

Metabolite T2 relaxation times decrease across the adult lifespan in a large multi-site cohort

PurposeRelaxation correction is crucial for accurately estimating metabolite concentrations measured using in vivo magnetic resonance spectroscopy (MRS). However, the majority of MRS quantification routines assume that relaxation values remain constant across the lifespan, despite prior evidence of T2 changes with aging for multiple of the major metabolites. Here, we comprehensively investigate correlations between T2 and age in a large, multi-site cohort. MethodsWe recruited approximately 10 male and 10 female participants from each decade of life: 18-29, 30-39, 40-49, 50-59, and 60+ years old (n=101 total). We collected PRESS data at 8 TEs (30, 50, 74, 101, 135, 179, 241, and 350 ms) from voxels placed in white-matter-rich centrum semiovale (CSO) and gray-matter-rich posterior cingulate cortex (PCC). We quantified metabolite amplitudes using Osprey and fit exponential decay curves to estimate T2. ResultsOlder age was correlated with shorter T2 for tNAA, tCr3.0, tCr3.9, tCho, Glx, and tissue water in CSO and PCC; rs = -0.21 to -0.65, all p<0.05, FDR-corrected for multiple comparisons. These associations remained statistically significant when controlling for cortical atrophy. T2 values did not differ across the adult lifespan for mI. By region, T2 values were longer in the CSO for tNAA, tCr3.0, tCr3.9, Glx, and tissue water and longer in the PCC for tCho and mI. ConclusionThese findings underscore the importance of considering metabolite T2 changes with aging in MRS quantification. We suggest that future 3T work utilize the equations presented here to estimate age-specific T2 values instead of relying on uniform default values.

neuroscience↗

bioRxiv2024

Model-based frequency-and-phase correction of 1H MRS data with 2D linear-combination modeling.

PurposeRetrospective frequency-and-phase correction (FPC) methods attempt to remove frequency- and-phase variations between transients to improve the quality of the averaged MR spectrum. However, traditional FPC methods like spectral registration struggle at low SNR. Here, we propose a method that directly integrates FPC into a two-dimensional linear-combination model (2D-LCM) of individual transients ( model-based FPC). We investigated how model-based FPC performs compared to the traditional approach, i.e., spectral registration followed by 1D-LCM in estimating frequency-and-phase drifts and, consequentially, metabolite level estimates. MethodsWe created synthetic in-vivo-like 64-transient short-TE sLASER datasets with 100 noise realizations at 5 SNR levels and added randomly sampled frequency and phase variations. We then used this synthetic dataset to compare the performance of 2D-LCM with the traditional approach (spectral registration, averaging, then 1D-LCM). Outcome measures were the frequency/phase/amplitude errors, the standard deviation of those ground-truth errors, and amplitude Cramer Rao Lower Bounds (CRLBs). We further tested the proposed method on publicly available in-vivo short-TE PRESS data. Results2D-LCM estimates (and accounts for) frequency-and-phase variations directly from uncorrected data with equivalent or better fidelity than the conventional approach. Furthermore, 2D-LCM metabolite amplitude estimates were at least as accurate, precise, and certain as the conventionally derived estimates. 2D-LCM estimation of frequency and phase correction and amplitudes performed substantially better at low-to-very-low SNR. ConclusionModel-based FPC with 2D linear-combination modeling is feasible and has great potential to improve metabolite level estimation for conventional and dynamic MRS data, especially for low-SNR conditions, e.g., long TEs or strong diffusion weighting.

neuroscience↗

bioRxiv2020

A new rat model of creatine transporter deficiency reveals behavioral disorder and altered brain metabolism

Creatine is an organic compound used as fast phosphate energy buffer to recycle ATP, important in tissues with high energy demand such as muscle or brain. Creatine is taken from the diet or endogenously synthetized by the enzymes AGAT and GAMT, and specifically taken up by the transporter SLC6A8. Deficit in the endogenous synthesis or in the transport leads to Cerebral Creatine Deficiency Syndromes (CCDS). CCDS are characterized by brain creatine deficiency, intellectual disability with severe speech delay, behavioral troubles such as attention deficits and/or autistic features, and epilepsy. Among CCDS, the X-linked creatine transporter deficiency (CTD) is the most prevalent with no efficient treatment so far. Different mouse models of CTD were generated by doing long deletions in the Slc6a8 gene showing reduced brain creatine and cognitive deficiencies or impaired motor function. We present a new knock-in (KI) rat model of CTD holding an identical point mutation found in patients with reported lack of transporter activity. KI males showed brain creatine deficiency, increased urinary creatine/creatinine ratio, cognitive deficiency and autistic features. Slc6a8xY389C KI rat fairly enriches the spectrum of CTD models and provides new data about the pathology, being the first animal model of CTD carrying a point mutation.

pathology↗